FDA ad­vi­so­ry com­mit­tee votes unan­i­mous­ly in fa­vor of bi­va­lent Covid shots re­plac­ing pri­ma­ry se­ries

The FDA’s Vac­cines and Re­lat­ed Bi­o­log­i­cal Prod­ucts Ad­vi­so­ry Com­mit­tee (VRB­PAC) vot­ed unan­i­mous­ly in fa­vor of “har­mo­niz­ing” Covid vac­cine com­po­si­tions, mean­ing all cur­rent vac­cine re­cip­i­ents would re­ceive a bi­va­lent vac­cine, re­gard­less of whether they’ve got­ten their pri­ma­ry se­ries.

The vote marks an ef­fort to clear up con­fu­sion around vary­ing for­mu­la­tions and dos­ing sched­ules for cur­rent pri­ma­ry se­ries and boost­er vac­cines, as well as “get clos­er to the strains that are cir­cu­lat­ing,” ac­cord­ing to com­mit­tee mem­ber Paul Of­fit, pro­fes­sor of pe­di­atrics at the Chil­dren’s Hos­pi­tal of Philadel­phia.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER